1. Rennie D. CONSORT revised—improving the reporting of randomized trials. JAMA 2001;285:2006-7. [PubMed] 2. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. [PubMed] 3. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials. JAMA 1998;279:1489-91. [PubMed]
4. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. 7th Cochrane Colloquium, Rome, Italy 1999.
5. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6. [PMC free article] [PubMed] 6. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-73. [PubMed] 7. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-83. [PubMed] 8. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 2000;136:381-5. [PubMed] 9. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology 1999;30:1134-8. [PubMed] 10. Schor S, Karten I. Statistical evaluation of medical journal manuscripts. JAMA 1966;195:1123-8. [PubMed] 11. Gore SM, Jones IG, Rytter EC. Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. BMJ 1977;1:85-7. [PMC free article] [PubMed] 12. Hall JC, Hill D, Watts JM. Misuse of statistical methods in the Australasian surgical literature. Aust N Z J Surg 1982;52:541-3. [PubMed] 13. Altman DG. Statistics in medical journals. Stat Med 1982;1:59-71. [PubMed] 14. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987;317:426-32. [PubMed] 16. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62. [PubMed] 17. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010;340:c723. [PMC free article] [PubMed] 18. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4. [PMC free article] [PubMed] 19. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. Ophthalmic Epidemiol 2007;14:390-8. [PubMed] 20. Moher D, Fortin P, Jadad AR, Jüni P, Klassen T, Le LJ, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996;347:363-6. [PubMed] 21. Junker CA. Adherence to published standards of reporting: a comparison of placebo-controlled trials published in English or German. JAMA 1998;280:247-9. [PubMed] 23. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125-8. [PubMed] 24. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 1948;2:769-82. [PMC free article] [PubMed] 25. Schulz KF. Randomized controlled trials. Clin Obstet Gynecol 1998;41:245-56. [PubMed] 26. Greenland S. Randomization, statistics, and causal inference. Epidemiology 1990;1:421-9. [PubMed] 27. Armitage P. The role of randomization in clinical trials. Stat Med 1982;1:345-52. [PubMed]
28. Kleijnen J, Gøtzsche PC, Kunz R, Oxman AD, Chalmers I. So what’s so special about randomisation. In: Maynard A, Chalmers I, eds. Non-random reflections on health services research BMJ Books, 1997:93-106.
29. Chalmers I. Assembling comparison groups to assess the effects of health care. J R Soc Med 1997;90:379-86. [PMC free article] [PubMed] 30. Nicolucci A, Grilli R, Alexanian AA, Apolone G, Torri V, Liberati A. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA 1989;262:2101-7. [PubMed] 31. Ah-See KW, Molony NC. A qualitative assessment of randomized controlled trials in otolaryngology. J Laryngol Otol 1998;112:460-3. [PubMed] 32. Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990;335:149-53. [PubMed] 33. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-4. [PMC free article] [PubMed] 34. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med 1982;306:1332-7. [PubMed] 35. A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. JAMA 1994;272:1926-31. [PubMed] 36. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Ann Intern Med 1994;121:894-5. [PubMed] 37. Rennie D. Reporting randomized controlled trials. An experiment and a call for responses from readers. JAMA 1995;273:1054-5. [PubMed] 38. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9. [PubMed] 39. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60. [PubMed] 40. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ 2004;328:702-8. [PMC free article] [PubMed] 41. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390. [PMC free article] [PubMed] 42. Ioannidis JP, Evans SJ, Gøtzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. [PubMed] 43. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295-309. [PubMed] 44. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006;144:364-7. [PubMed] 45. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20. [PMC free article] [PubMed] 46. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339-41. [PubMed] 47. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. [PMC free article] [PubMed]
48. Lang TA, Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers ACP, 1997.
49. Davidoff F. News from the International Committee of Medical Journal Editors. Ann Intern Med 2000;133:229-31. [PubMed] 50. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006;185:263-7. [PubMed] 51. Egger M, Jüni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996-9. [PubMed] 52. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62. [PubMed] 53. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91. [PubMed] 54. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4. [PubMed] 55. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. [PubMed] 56. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the Lancet. Lancet 2008;372:201. [PubMed] 57. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 2008;3:e3081. [PMC free article] [PubMed] 58. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94. [PubMed] 59. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [PMC free article] [PubMed]
60. Pocock SJ. Clinical trials: a practical approach John Wiley, 1983.
61. Meinert CL. Clinical trials: design, conduct and analysis Oxford University Press, 1986.
62. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials 3rd ed. Springer, 1998.
63. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000;321:329-33. [PMC free article] [PubMed] 64. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration’s CENTRAL Register of controlled clinical trials. Eval Health Prof 2002;25:38-64. [PubMed] 65. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008;371:281-3. [PubMed] 67. Harbourt AM, Knecht LS, Humphreys BL. Structured abstracts in MEDLINE, 1989-1991. Bull Med Libr Assoc 1995;83:190-5. [PMC free article] [PubMed] 68. Harris AH, Standard S, Brunning JL, Casey SL, Goldberg JH, Oliver L, et al. The accuracy of abstracts in psychology journals. J Psychol 2002;136:141-8. [PubMed] 69. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:1110-1. [PubMed] 70. Ward LG, Kendrach MG, Price SO. Accuracy of abstracts for original research articles in pharmacy journals. Ann Pharmacother 2004;38:1173-7. [PubMed] 71. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ 2006;333:231-4. [PMC free article] [PubMed] 72. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. [PubMed] 73. Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. Ann Intern Med 1990;113:69-76. [PubMed] 74. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR. Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ 1994;150:1611-5. [PMC free article] [PubMed] 75. Wager E, Middleton P. Technical editing of research reports in biomedical journals. Cochrane Database Syst Rev 2008;MR000002. [PubMed]
76. Hartley J, Sydes M, Blurton A. Obtaining information accurately and quickly: Are structured abstracts more efficient? J Inform Sci 1996;22:349-56.
77. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-37. [PubMed] 78. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999;341:1801-6. [PubMed] 79. World Medical Association. Declaration of Helsinki: ethical principle for medical research involving human subjects. 59th WMA General Assembly, Seoul 2008; www.wma.net/e/policy/b3.htm (accessed 2 June 2009). 80. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54. [PubMed] 81. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005;2:218-29. [PubMed] 82. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ 1996;313:1390-3. [PMC free article] [PubMed] 83. Sadler LC, Davison T, McCowan LM. A randomised controlled trial and meta-analysis of active management of labour. BJOG 2000;107:909-15. [PubMed] 84. Bath FJ, Owen VE, Bath PM. Quality of full and final publications reporting acute stroke trials: a systematic review. Stroke 1998;29:2203-10. [PubMed] 85. Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics 2009;123:e770-e776. [PubMed] 86. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-95. [PubMed] 87. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005;9:1-iv. [PubMed]
88. Gallo P, Krams M. PhRMA Working Group on adaptive designs, “White Paper.” Drug Information Journal 2006;40:421-82.
89. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthen B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health 2009;30:1-25. [PMC free article] [PubMed] 90. Kelly PJ, Sooriyarachchi MR, Stallard N, Todd S. A practical comparison of group-sequential and adaptive designs. J Biopharm Stat 2005;15:719-38. [PubMed] 91. Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 2005;330:1049. [PMC free article] [PubMed] 92. Chan AW, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:a2299. [PMC free article] [PubMed] 93. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 2009;338:1867-75. [PMC free article] [PubMed] 94. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365:82-93. [PubMed] 95. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 1998;51:69-79. [PubMed] 96. Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epidemiol 2000;53:973-9. [PubMed] 97. Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005;19:1885-96. [PubMed] 98. Hall JC, Mills B, Nguyen H, Hall JL. Methodologic standards in surgical trials. Surgery 1996;119:466-72. [PubMed] 99. Weiss NS, Koepsell TD, Psaty BM. Generalizability of the results of randomized trials. Arch Intern Med 2008;168:133-5. [PubMed] 100. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47. [PubMed] 101. Rannou F, Dimet J, Boutron I, Baron G, Fayad F, Macé Y, et al. Splint for base-of-thumb osteoarthritis: a randomized trial. Ann Intern Med 2009;150:661-9. [PubMed] 102. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ 2008;336:1472-4. [PMC free article] [PubMed] 103. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. [PubMed]
104. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 3rd ed. New York: Oxford University Press, 2006.
105. Streiner D, Norman C. Health measurement scales: a practical guide to their development and use. 3rd ed. Oxford: Oxford University Press; 2003.
106. Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials 2007;8:39. [PMC free article] [PubMed] 107. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998;317:1191-4. [PMC free article] [PubMed] 108. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 1989;10:31-56. [PubMed] 109. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000;176:249-52. [PubMed]
110. Jadad AR, Boyle M, Cunnigham C, Kim M, Schachar R. Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No. 11. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality. AHQR publication no. 00-E005; 1999.
111. Schachter HM, Pham B, King J, Langford S, Moher D. The efficacy and safety of methylphenidate in attention deficit disorder: A systematic review and meta-analyis. Prepared for the Therapeutics Initiative, Vancouver, B.C., and the British Columbia Ministry for Children and Families, 2000.
112. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. [PubMed] 113. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40. [PMC free article] [PubMed] 114. Vermeulen H, Hofland J, Legemate DA, Ubbink DT. Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial. Trials 2009;10:50. [PMC free article] [PubMed] 115. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16. [PubMed] 116. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995;311:1145-8. [PMC free article] [PubMed] 117. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med 2008;5:e4. [PMC free article] [PubMed] 118. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet 2005;365:1348-53. [PubMed] 119. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62. [PubMed] 120. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485. [PMC free article] [PubMed] 121. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994;272:122-4. [PubMed] 122. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. N Engl J Med 1978;299:690-4. [PubMed] 123. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ 2009;338:b1732. [PMC free article] [PubMed] 124. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-22. [PubMed] 125. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994;121:200-6. [PubMed] 126. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000;133:676-86. [PubMed] 127. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78. [PubMed] 128. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987;43:213-23. [PubMed] 129. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med 1985;4:521-6. [PubMed] 131. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet 1999;354:1983-8. [PubMed] 132. Buyse M. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Stat Med 1993;12:509-20. [PubMed] 133. Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials 2004;1:48-59. [PubMed] 134. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-9. [PubMed] 135. Coutinho IC, Ramos de Amorim MM, Katz L, Bandeira de Ferraz AA. Uterine exteriorization compared with in situ repair at cesarean delivery: a randomized controlled trial. Obstet Gynecol 2008;111:639-47. [PubMed]
136. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context BMJ Books, 2001.
137. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008;111:267-77. [PubMed] 138. Tate DF, Jackvony EH, Wing RR. Effects of internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA 2003;289:1833-6. [PubMed] 139. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials 1988;9:312-26. [PubMed] 140. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612. [PMC free article] [PubMed]
141. Schulz KF, Grimes DA. The Lancet handbook of essential concepts in clinical research Elsevier, 2006.
143. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8. [PubMed]
144. Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials: prevention of poststudy anxiety. Drug Information Journal 1990;24:541-8.
145. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn’t guarantee similarity of groups; minimisation does. BMJ 1998;317:362-3. [PMC free article] [PubMed] 146. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990;97:412-9. [PubMed] 147. Radford JA, Landorf KB, Buchbinder R, Cook C. Effectiveness of low-Dye taping for the short-term treatment of plantar heel pain: a randomised trial. BMC Musculoskelet Disord 2006;7:64. [PMC free article] [PubMed] 148. Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med 1987;6:315-28. [PubMed]
149. Pocock SJ. Statistical aspects of clinical trial design. Statistician 1982;31:1-18.
150. Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Information Journal 1998;32:11.
151. Piaggio G, Elbourne D, Schulz KF, Villar J, Pinol AP, Gülmezoglu AM. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. BMC Med Res Methodol 2003;3:19. [PMC free article] [PubMed] 152. Pildal J, Hróbjartsson A, Jórgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 2007;36:847-57. [PubMed] 153. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5. [PMC free article] [PubMed] 154. McCandlish R, Bowler U, van Asten H, Berridge G, Winter C, Sames L, et al. A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol 1998;105:1262-72. [PubMed] 155. Webster J, Clarke S, Paterson D, Hutton A, van Dyk S, Gale C, et al. Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. BMJ 2008;337:a339. [PMC free article] [PubMed] 156. Smith SA, Shah ND, Bryant SC, Christianson TJ, Bjornsen SS, Giesler PD, et al. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc 2008;83:747-57. [PubMed] 157. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-73. [PMC free article] [PubMed] 158. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med 1998;72:389-433. [PubMed] 159. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, et al. Effect of encouragement on walking test performance. Thorax 1984;39:818-22. [PMC free article] [PubMed] 160. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials 1996;17:285-90. [PubMed] 161. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA 1975;231:1038-42. [PubMed] 162. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44:16-20. [PubMed] 163. Carley SD, Libetta C, Flavin B, Butler J, Tong N, Sammy I. An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb. BMJ 2000;321:20. [PMC free article] [PubMed] 164. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002;136:254-9. [PubMed] 165. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ 2000;321:504. [PMC free article] [PubMed] 166. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002;55:787-90. [PubMed] 167. Cheng K, Smyth RL, Motley J, O’Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000;29:1-7. [PubMed] 168. Lang T. Masking or blinding? An unscientific survey of mostly medical journal editors on the great debate. Med Gen Med 2000;2:E25. [PubMed] 169. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-3. [PubMed] 170. Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials 2006;3:360-5. [PubMed] 171. Meinert CL. Masked monitoring in clinical trials—blind stupidity? N Engl J Med 1998;338:1381-2. [PubMed] 172. Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol 2003;3:4. [PMC free article] [PubMed] 173. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ 1996;312:742-4. [PMC free article] [PubMed] 174. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 2004;328:432. [PMC free article] [PubMed] 175. Sackett DL. Turning a blind eye: why we don’t test for blindness at the end of our trials. BMJ 2004;328:1136. [PMC free article] [PubMed] 176. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al HM, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16. [PubMed]
177. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence: confidence intervals and statistical guidelines 2nd ed. BMJ Books, 2000:171-90.
179. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol 1998;38:408-12. [PubMed] 180. Greenland S. Principles of multilevel modelling. Int J Epidemiol 2000;29:158-67. [PubMed] 181. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299:2027-36. [PMC free article] [PubMed] 182. Matthews JN, Altman DG. Interaction 3: How to examine heterogeneity. BMJ 1996;313:862. [PMC free article] [PubMed] 183. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9. [PubMed] 184. Matthews JN, Altman DG. Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ 1996;313:808. [PMC free article] [PubMed] 185. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84. [PubMed] 186. Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J 2000;139:745-51. [PubMed]
187. Altman DG. Adjustment for covariate imbalance. In: Armitage P, Colton T, eds. Encyclopedia of biostatistics John Wiley, 1998:1000-5.
188. Mullner M, Matthews H, Altman DG. Reporting on statistical methods to adjust for confounding: a cross-sectional survey. Ann Intern Med 2002;136:122-6. [PubMed] 189. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10. [PubMed] 190. Bender R, Grouven U. Logistic regression models used in medical research are poorly presented. BMJ 1996;313:628. [PMC free article] [PubMed] 191. Khan KS, Chien PF, Dwarakanath LS. Logistic regression models in obstetrics and gynecology literature. Obstet Gynecol 1999;93:1014-20. [PubMed] 192. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2. [PubMed] 193. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation 1981;64:669-73. [PubMed] 194. Altman DG, Cuzick J, Peto J. More on zidovudine in asymptomatic HIV infection. N Engl J Med 1994;330:1758-9. [PubMed] 195. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA 1998;279:1487-9. [PubMed] 196. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ 2008;337:a2664. [PMC free article] [PubMed] 197. van Loon AJ, Mantingh A, Serlier EK, Kroon G, Mooyaart EL, Huisjes HJ. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term. Lancet 1997;350:1799-804. [PubMed] 198. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72. [PubMed] 199. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133:516-26. [PubMed] 200. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991;9:191-2. [PubMed] 201. Altman DG, de Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511-8. [PMC free article] [PubMed] 202. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298. [PMC free article] [PubMed] 203. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ 2000;321:931-3. [PMC free article] [PubMed] 204. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999;353:943-4. [PubMed] 205. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988;7:1231-42. [PubMed] 206. Kiri A, Tonascia S, Meinert CL. Treatment effects monitoring committees and early stopping in large clinical trials. Clin Trials 2004;1:40-7. [PubMed] 207. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 2003;289:2128-31. [PubMed] 208. Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med 2006;25:3245-9. [PubMed] 209. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83. [PubMed]
210. Senn S. Base logic: tests of baseline balance in randomized clinical trials. Clin Res Regulatory Affairs 1995;12:171-82.
211. Altman DG. Comparability of randomised groups. Statistician 1985;34:125-36.
212. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:853-61. [PubMed] 213. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000;119:639-46. [PubMed] 214. Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, Macdonald M. Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. JAMA 1970;211:1993-2003. [PubMed] 215. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med 1991;10:1595-605. [PubMed] 216. Lewis JA, Machin D. Intention to treat—who should use ITT? Br J Cancer 1993;68:647-50. [PMC free article] [PubMed] 217. Lachin JL. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:526. [PubMed] 218. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995;57:6-15. [PubMed] 219. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 2000;19:1849-64. [PubMed] 220. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3. [PMC free article] [PubMed] 221. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials 2007;4:350-6. [PubMed] 222. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out? J Fam Pract 2002;51:969-71. [PubMed] 223. Herman A, Botser IB, Tenenbaum S, Chechick A. Intention-to-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. J Bone Joint Surg Am 2009;91:2137-43. [PubMed] 224. Ruiz-Canela M, Martinez-González MA, de Irala-Estévez J. Intention to treat analysis is related to methodological quality. BMJ 2000;320:1007-8. [PMC free article] [PubMed] 225. Altman DG. Missing outcomes in randomised trials: addressing the dilemma. Open Med 2009;3:e21-3. [PMC free article] [PubMed] 226. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 2004;1:368-76. [PubMed] 227. Streiner DL. Missing data and the trouble with LOCF. Evid Based Ment Health 2008;11:3-5. [PubMed] 228. Molnar FJ, Hutton B, Fergusson D. Does analysis using “last observation carried forward” introduce bias in dementia research? CMAJ 2008;179:751-3. [PMC free article] [PubMed] 229. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003;348:2136-7. [PubMed] 230. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68-75. [PubMed] 231. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-106. [PubMed]
232. Abraha I, Montedori A, Romagnoli C. Modified intention to treat: frequency, definition and implication for clinical trials [abstract]. Sao Paulo, Brazil: XV Cochrane Colloquium, 2007: 86-7.
233. Altman DG. Confidence intervals in practice. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence 2nd ed. BMJ Books, 2000:6-14.
234. van Linschoten R, van Middelkoop M, Berger MY, Heintjes EM, Verhaar JA, Willemsen SP, et al. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. BMJ 2009;339:b4074. [PMC free article] [PubMed]
235. Altman DG. Clinical trials and meta-analyses. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence 2nd ed. BMJ Books, 2000:120-38.
236. Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. Ann Intern Med 1997;126:36-47. [PubMed] 237. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ 1986;292:746-50. [PMC free article] [PubMed] 238. Bailar JC, III, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med 1988;108:266-73. [PubMed] 239. Bland JM. Quoting intermediate analyses can only mislead. BMJ 1997;314:1907-8. [PMC free article] [PubMed] 240. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4. [PMC free article] [PubMed] 241. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5. [PMC free article] [PubMed] 242. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant—the judgment of OSIRIS (open study of infants at high risk of or with respiratory insufficiency—the role of surfactant). Lancet 1992;340:1363-9. [PubMed] 243. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexøe J, Nielsen JB. Laypersons’ understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak 2008;8:31. [PMC free article] [PubMed] 244. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet 1994;343:1209-11. [PubMed] 245. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21. [PubMed] 246. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84. [PubMed] 247. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8. [PubMed] 248. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med 2000;19:3325-36. [PubMed] 249. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schünemann HJ, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006;447:247-51. [PubMed] 250. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356:961-7. [PubMed] 251. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006;24:3933-8. [PubMed] 252. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61. [PubMed] 253. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16. [PubMed] 255. Annals of Internal Medicine. Information for authors. Available at www.annals.org (accessed 15 Jan 2008). 256. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999;318:1224-5. [PMC free article] [PubMed] 257. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. JAMA 1998;280:227-8. [PubMed] 258. Ioannidis JP. Limitations are not properly acknowledged in the scientific literature. J Clin Epidemiol 2007;60:324-9. [PubMed] 259. Kiviluoto T, Sirén J, Luukkonen P, Kivilaakso E. Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis. Lancet 1998;351:321-5. [PubMed] 260. Hupperets MD, Verhagen EA, van Mechelen W. Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial. BMJ 2009;339:b2684. [PMC free article] [PubMed] 261. Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA 2009;301:2215-24. [PMC free article] [PubMed] 262. Campbell D. Factors relevant to the validity of experiments in social settings. Psychol Bull 1957;54:297-312. [PubMed] 263. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 2006;1:e9. [PMC free article] [PubMed] 264. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials. Health Technol Assess 2005;9:1-iv. [PubMed] 265. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8. [PubMed] 266. Dans AL, Dans LF, Guyatt GH, Richardson S. Users’ guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 1998;279:545-9. [PubMed] 267. Smith GD, Egger M. Who benefits from medical interventions? BMJ 1994;308:72-4. [PMC free article] [PubMed]
268. McAlister FA. Applying the results of systematic reviews at the bedside. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care: meta-analysis in context BMJ Books, 2001.
269. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9:iii-x, 1. [PubMed] 270. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ 2006;333:346-9. [PMC free article] [PubMed] 271. Bornhöft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, et al. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol 2006;6:56. [PMC free article] [PubMed] 272. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33. [PubMed] 273. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12. [PMC free article] [PubMed] 274. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1994;330:1107-13. [PubMed] 275. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66. [PubMed] 276. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8. [PMC free article] [PubMed] 277. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med 2007;100:187-90. [PMC free article] [PubMed] 278. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999;130:995-1004. [PubMed] 280. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-42. [PubMed] 281. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev 1997;9:15-21. [PubMed] 282. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115. [PubMed] 283. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med 2005;24:1547-61. [PubMed] 284. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40. [PMC free article] [PubMed] 285. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41. [PubMed] 286. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-41. [PMC free article] [PubMed] 288. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23. [PubMed] 289. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5. [PubMed] 290. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-9. [PubMed] 291. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA 2007;297:2112-20. [PubMed] 292. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal ‘instructions to authors’. Trials 2008;9:20. [PMC free article] [PubMed] 293. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. [PubMed]
294. Chan AW, Tetzlaff J, Altman D, Gøtzsche PC, Hróbjartsson A, Krleza-Jeric K, et al. The SPIRIT initiative: defining standard protocol items for randomised trials. Oral presentation at the 16th Cochrane Colloquium: Evidence in the era of globalisation; 2008 Oct 3-7; Freiburg, Germany [abstract]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2008;102:27.
295. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med 2007;4:e102. [PMC free article] [PubMed] 296. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-9. [PubMed] 297. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70. [PMC free article] [PubMed] 298. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002;325:249. [PMC free article] [PubMed] 299. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 2007;4:e184. [PMC free article] [PubMed] 300. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2008;29:109-13. [PubMed] 301. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290:921-8. [PubMed] 302. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-12. [PubMed] 303. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289:2545-53. [PubMed]
304. Senn S. Crossover trials in clinical research. 2nd ed. Wiley, 2002.
305. Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii-173. [PubMed] 306. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007;MR000012. [PubMed] 307. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001;357:373-80. [PubMed] 308. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet 1996;348:596-8. [PubMed] 309. Murray GD. Promoting good research practice. Stat Methods Med Res 2000;9:17-24. [PubMed] 310. Narahari SR, Ryan TJ, Aggithaya MG, Bose KS, Prasanna KS. Evidence-based approaches for the Ayurvedic traditional herbal formulations: toward an Ayurvedic CONSORT model. J Altern Complement Med 2008;14:769-76. [PubMed] 311. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 2003;138:40-4. [PubMed] 312. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7. [PubMed] 313. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-24. [PubMed]